News for PMGC Holdings Inc. Stock (ELAB)

Elevai Labs Inc. Announces Name Change to PMGC Holdings Inc. and Redomicile to Nevada

GlobeNewsWire • 12/21/24

Elevai Labs Inc. Announces Anticipated Name Change to PMGC Holdings Inc. and Redomicile to Nevada

GlobeNewsWire • 12/20/24

Elevai Labs Inc. Subsidiary, Elevai Skincare, Launches S-Series Root Renewal System, Marking Entry into Hair Care Market

GlobeNewsWire • 12/06/24

Elevai Labs Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance

GlobeNewsWire • 11/22/24

Elevai Labs Inc. Announces Withdrawal of Offer to Exchange and Plans to Reassess

GlobeNewsWire • 11/22/24

CORRECTION - Elevai Labs Inc.

GlobeNewsWire • 11/14/24

Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update

GlobeNewsWire • 11/14/24

Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange

GlobeNewsWire • 11/04/24

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity

GlobeNewsWire • 10/22/24

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity

GlobeNewsWire • 10/21/24

Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock

GlobeNewsWire • 10/04/24

REPEAT: Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations

GlobeNewsWire • 10/03/24

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations

GlobeNewsWire • 10/03/24

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Launch of Clinical Study Combining Its Flagship Topical Exosome Skincare Products with a Medical Aesthetic Energy Device

GlobeNewsWire • 10/02/24

Univest Securities, LLC Announces Closing of $8.0 Million Registered Follow-on Offering for its Client Elevai Labs Inc. (NASDAQ: ELAB)

GlobeNewsWire • 09/24/24

Dow Gains Over 50 Points; Elevai Labs Shares Plummet

Benzinga • 09/23/24

Elevai Labs Inc. Announces Pricing of $8.0 Million Public Offering

GlobeNewsWire • 09/23/24

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Results for E-Series Exosome Technology in Potential Melasma Applications

GlobeNewsWire • 09/10/24

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Encouraging Data Results Indicating Potential for Hair Restoration Using Proprietary Exosome Technology

GlobeNewsWire • 09/03/24

Elevai Labs Inc. Files Combination Patents with Yuva Biosciences for Breakthrough Hair and Scalp Care Technology Utilizing YuvaBioⓇ Y100™ Mitochondrial Innovation and Elevai Exosomes™

GlobeNewsWire • 08/28/24

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Data Results with Completion of Clinical Study of Elevai Enfinity™ Topical Exosome Serum

GlobeNewsWire • 08/26/24

Elevai Labs Inc. Subsidiary, Elevai Research Inc., Announces Preliminary Positive Research Data Highlighting the Potential of Proprietary Exosome Technology for Skin Health Applications

GlobeNewsWire • 08/19/24

Elevai Labs Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewsWire • 08/14/24

Elevai Labs Inc. Subsidiary, Elevai Biosciences, Continues to Advance its Scientific Advisory Board with the Appointment of Orian Shirihai, MD, PhD

GlobeNewsWire • 07/30/24

Top 4 Risk Off Stocks You'll Regret Missing In July

Benzinga • 07/16/24